Özet Yaşamın ileri dönemlerinde kardiyovasküler olayları azaltmak için dislipidemi ve hipertansiyon gibi anahtar risk faktörlerinin ortadan kaldırılması önemlidir. Tıbbi öykü, fizik muayene ve lipid ve glikolize hemoglobin düzeyleri ölçümlerini içeren laboratuvar incelemeleri kardiyovasküler riskin iyi bir şekilde değerlendirilmesini sağlar. Hastaların çoğunda birincil lipid hedefi olan LDL-C düzeyini düşürmek için ilk seçilecek tedavi statindir. İstenilen hedef düzeylere erişmek için yüksek doz statin tedavisi gerekebilir. Başlangıçta antihipertansif tedavi seçimi hastanıneş zamanlı hastalıklarına ve ilacın yan etkilerine bağlıdır, ancak hastaların çoğunda hedefe erişmek için antihipertan-sif tedavi kombinasyonu gerekebilir. Sigarayı bırakma ve diğer risk faktörlerinin değiştirilmesi ile bu çok faktörlü risk yaklaşımı kombinasyonu, erkekler için güncel ve gelecekteki kardiyovasküler yönetim olmalıdır.
■ Kaynaklar1.Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125(1): e2-e220.
2.Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): casecontrol study. Lancet. 2004;364(9438):937-952.
3.Mensah GA, Brown DW, Croft JB, Greenlund KJ. Major coronary risk factors and death from coronary heart disease: baseline and follow-up mortality data from the Second National Health and Nutrition Examination Survey (NHANES II). Am J Prev Med. 2005;29(5 suppl l):68-74.
4.Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96(4):556-563.
5.Waters DD, Brotons C, Chiang CW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density
6.Vande Griend JP, Saseen JJ. Low-density lipoprotein cholesterol goal attainment in high-risk family medicine patients. J Clin Lipidol. 2009;3(3): 195-200.
7.Barham AH, Goff DC Jr, Chen H, et al. Appropriateness of cholesterol management in primary care by sex and level of cardiovascular risk. Prev Cardiol. 2009;12(2): 95-101.
8.Kitkungvan D, Lynn Fillipon NM, Dani SS, Downey BC. Lowdensity lipoprotein cholesterol target achievement in patients at high risk for coronary heart disease. J Clin Lipidol. 2010;4(4):293-297.
9.Leiter LA, Lundman P, da Silva PM, et al. Persistent lipid abnormalities in statintreated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med. 2011;28( 11):1343-1351.
10.Rallidis LS, Kotakos C, Sourides V, et al. Attainment of optional low-density lipoprotein cholesterol goal of less than 70 mg/dl and impact on prognosis of very high risk stable coronary patients: a 3-year follow-up. Expert Opin Pharmacother. 2011; 12(10): 1481-1489.
11.Centers for Disease Control and Prevention. High blood pressure facts.
http://www. cdc.gov/bloodpressure/facts.htm. Published 2012. Accessed May 2, 2012.
12.Egan BM, Zhao Y, Axon RN. US trends in prevalence, awarness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303(20):2043-2050.
13.McClave A, Rock V, Thorne S, Malarcher A. State-specific prevalence of cigarette smoking and smokeless tobacco use among adults—United States, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(43):1400-1406.
14.Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366(4):321-329.
15.Lewis SJ, Fox KM, Grandy S; Shield Study Group. Selfreported diagnosis of heart disease: results from the SHIELD study. Int J Clin Pract. 2009;63(5):726-734.
16.National Center for Health Statistics. Health, United States, 2010: with special feature on death and dying.
http://www.cdc.gov/nchs/data/hus/huslO.pdf. Published 2011. Accessed May 2, 2012.
17.Hemann BA, Bimson WF, Taylor AJ. The Framingham Risk Score: an appraisal of its benefits and limitations. Am Heart Hosp J. 2007;5(2):91-96.
18.Karim R, Hodis HN, Detrano R, Liu CR, Liu CH, Mack WJ. Relation of Framingham risk score to subclinical atherosclerosis evaluated across three arterial sites. Am J Cardiol. 2008;102(7):825-830.
19.Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297(6):611-619.
20.Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008; 118(22):2243-2251.
21.Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51 ( 15): 1512-1524.
22.Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vase Dis Res. 2008;5(4):319-335.
23.Koz C, Baysan O, Hasimi A, et al. Conventional and non-con-ventional coronary risk factors in male premature coronary artery disease patients already having a low Framingham risk score. Acta Cardiol. 2008;63(5):623-628.
24.Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vase Biol. 2007;27( 1): 15 26.
25.Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511.
26.Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
27.Di Angelantonio E, Sarwar N, Perry P, et al; Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302( 18): 1993- 2000.
28.Blackburn P, Lemieux I, Almeras N, et al. The hypertriglyce-ridemic waist phenotype versus the National Cholesterol Education Program-Adult Treatment Panel III and International Diabetes Federation clinical criteria to identify highrisk men with an altered cardiometabolic risk profile. Metabolism. 2009;58(8 ): 1123-1130.
29.Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20): 1615-1622.
30.Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361 (9364): 1149-1158.
31.Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20): 1301-1307.
32.Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2):227-239.
33.Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21): 2195-2207.
34.Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670): 1175-1182.
35.Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther. 2009;31(2): 236-244.
36.Chan DK, O’Rourke F, Shen Q, Mak JC, Hung WT. Metaanalysis of the cardiovascular benefits of intensive lipid lowering with statins. Acta Neurol Scand. 2011;124(3): 188-195.
37.Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-2087.
38.Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
39.Whitworth JA World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hyper-tens. 2003;21(11):1983-1992.
40.National Clinical Guideline Centre. Hypertension: the clinical management of primary hypertension in adults, http://
www.nice.org.uk/ nicemedia/ live/12167/54727/54727.pdf. Published 2011. Accessed May 2, 2012.
41.Cushman WC, Ford CE, Cutler JA, et al. Success and predic-
tors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393-404.
42.Chen JM, Heran BS, Wright JM. Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension. Cochrane Database Syst Rev. 2009;(4):CD007187.
43.Heran BS, Chen JM, Wang JJ, Wright JM. Blood pressure lowering efficacy of potassium- sparing diuretics (that block the epithelial sodium channel) for primary hypertension. Cochrane Database Syst Rev. 2010;(1):CD008167.
44.Batterink J, Stabler SN, Tejani AM, Fowkes CT. Spironolactone for hypertension. Cochrane Database Syst Rev. 2010;(8 ):CD008169.
45.Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2008;(4):CD003822.
46.Grosso AM, Bodalia PN, Macallister RJ, Hingorani AD, Moon JC, Scott MA. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. Int J Clin Pract. 2011;65(3):253-263.
47.Nixon RM, Müller E, Lowy A, Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int J Clin Pract. 2009;63(5):766-775.
48.Zhenfeng Z, Huilan S, Junya J, Dong L, Shan L. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. J Renin Angiotensin Aldosterone Syst. 2011;12(3):365-374.
49.Zheng Z, Lin S, Shi H. A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension. J Clin Hypertens (Greenwich). 2010; 12(6):414-421.
50.Kjeldsen SE, Stàlhammar J, Hasvole P, Bodegard J, Olsson U,Russell D. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. J Hum Hypertens. 2010;24(4):263-273.
51.Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2008;(4):CD003823.
Michael E. Cobble, MD, AAFP, FNLA
Director, Canyons Medical Center, Adjunct Faculty, University of Utah School of Medicine, Sandy, UT, Chief Medical Officer, Atherotech, Birmingham, AL
Supplement to The Journal of Family Practice, Vol 61, No 6:S29-S33, June 2012